0.25mg Tirzepatide: Understanding the Starting Dose Decision

Why 0.25mg exists, and what it is not trying to do yet

If you've just received your first Mounjaro prescription and noticed the pen says 0.25mg, it's entirely reasonable to wonder whether that's enough to do anything. The honest answer is: at this dose, the aim is settling in, not slimming down. Tirzepatide activates two distinct gut-hormone pathways (the GIP receptor and the GLP-1 receptor) and that dual action, while effective at higher strengths, can produce noticeable nausea and digestive disruption when introduced too quickly. The 0.25mg starting dose is calibrated to introduce the mechanism gently, giving the body four weeks to adjust before the first increase.

This is not a concession or a half-measure. It is how the medicine was designed to be used, and it reflects the clinical reality that people who rush through the early doses tend to experience more side effects, not fewer. The full tirzepatide titration schedule runs from 2.5mg upward through six dose levels to a maximum of 15mg; the 0.25mg introductory pen is the threshold step before that programme begins. You will typically move to 2.5mg after four weeks, subject to how you're tolerating the medicine, a conversation your prescriber will have with you at each review.

One thing worth knowing: if you're feeling a little impatient at this stage, that's genuinely understandable. Many people come to tirzepatide after months or years of trying other approaches, and starting on a dose that isn't therapeutically active yet can feel anticlimactic. That feeling is normal, and it does not last long.

What to expect during those first four weeks on 0.25mg

Side effects at 0.25mg tirzepatide are generally milder than at higher doses, though they can still be noticeable. The most commonly reported are gastrointestinal: nausea, loose stools, constipation, indigestion and reduced appetite. These tend to be most prominent in the day or two after an injection and improve as the weeks progress. The step to 5mg may bring a second adjustment wave, which is why the gradual titration exists in the first place.

Injection technique matters from the very first pen. The recommended sites are the abdomen, thigh or upper arm, rotated between doses. Storage is in the fridge at 2–8°C; the exact window for room-temperature use is set out in the Patient Information Leaflet and the Mounjaro SmPC on the eMC, which is the authoritative source for storage and handling, not a summary page.

If you experience severe, persistent stomach pain that spreads toward the back, seek medical attention promptly. The MHRA has highlighted acute pancreatitis as an infrequent but serious risk with GLP-1 medicines, and early symptoms should not be dismissed as ordinary nausea. Any suspected side effect can be reported directly through the MHRA's Yellow Card scheme.

Two practical notes: women taking oral contraceptives should add a barrier method for the first four weeks of tirzepatide treatment and for four weeks after each dose increase, as absorption of the pill may be reduced. And if you have any surgical procedure coming up, tell the anaesthetist you are on this medicine.

Who the prescriber is assessing when they set your starting dose

Tirzepatide is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as hypertension, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The 0.25mg Mounjaro pen is the standard starting point for virtually everyone who begins treatment, regardless of starting weight or BMI.

That said, BMI alone does not determine suitability. A prescriber also considers existing conditions, current medications and any contraindications, including a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, and certain gastrointestinal conditions. Pregnancy, breastfeeding and trying to conceive are all situations in which these medicines are not recommended. Treatment is not licensed for anyone under 18.

NICE's appraisal of tirzepatide, TA1026, sets out the NHS-pathway criteria separately. Private prescribing follows the licensed indication from the SmPC rather than the NHS commissioning criteria, which are narrower. For a clear overview of cost context in the private market, the Mounjaro price comparison page sets out what to look for beyond the headline figure.

Moving beyond 0.25mg, what that decision looks like

After four weeks, a prescriber will typically review how you have tolerated the 0.25mg pen before confirming your next dose. This is not a box-ticking exercise. Factors that influence the decision include severity of side effects, any change in clinical parameters, and whether circumstances have changed since your initial consultation. If tolerability has been good, progression to 5mg tirzepatide via the 2.5mg step is the usual path. If you have struggled, a slower pace is clinically appropriate and the titration can be extended.

The clinical trial evidence (from SURMOUNT-1, published in the New England Journal of Medicine) showed average body-weight reductions of around 20–21% at the highest dose over 72 weeks. Those results are produced across the full titration schedule, not from remaining at the starting dose. The intermediate dose steps are as much a part of the treatment as the maintenance phase.

If you are still deciding whether tirzepatide is the right route and want to understand the broader range of options, the weight loss treatment overview covers how different approaches compare. And if you are ready to find out whether you are clinically suitable, a free consultation with our prescribers is the place to start, reviewed the same day by a real clinician, not software.